TUBB Stock Overview
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Financière de Tubize SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €95.25 |
| 52 Week High | €68.30 |
| 52 Week Low | €68.30 |
| Beta | 0.47 |
| 1 Month Change | 6.19% |
| 3 Month Change | 23.94% |
| 1 Year Change | n/a |
| 3 Year Change | 17.52% |
| 5 Year Change | 57.18% |
| Change since IPO | 221.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| TUBB | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 4.4% | 6.3% | 1.1% |
| 1Y | n/a | 5.7% | 1.9% |
Return vs Industry: Insufficient data to determine how TUBB performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TUBB performed against the UK Market.
Price Volatility
| TUBB volatility | |
|---|---|
| TUBB Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: TUBB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TUBB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1928 | n/a | Eric Nys | www.financiere-tubize.be |
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Financière de Tubize SA Fundamentals Summary
| TUBB fundamental statistics | |
|---|---|
| Market cap | €4.33b |
| Earnings (TTM) | €88.15m |
| Revenue (TTM) | n/a |
49.1x
P/E Ratio0.0x
P/S RatioIs TUBB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TUBB income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €2.03m |
| Gross Profit | -€2.03m |
| Other Expenses | -€90.18m |
| Earnings | €88.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 1.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.4% |
How did TUBB perform over the long term?
See historical performance and comparison